Amanote Research
Register
Sign In
Entering a New Era – Prostate Cancer Immuno-Therapy After the FDA Approval for Sipuleucel-T
doi 10.5772/25553
Full Text
Open PDF
Abstract
Available in
full text
Date
November 25, 2011
Authors
Thomas H.
Publisher
InTech
Related search
Sipuleucel-T: Immunotherapy for Advanced Prostate Cancer
Research and Reports in Urology
Urology
Percent Free Prostate-Specific Antigen: Entering a New Era in the Detection of Prostate Cancer
Mayo Clinic Proceedings
Medicine
CAR-T Based Immuno-Therapy: New Hope for Cancer Patients
Journal of Tumor Medicine & Prevention
FDA Approval of New Drugs
JAMA - Journal of the American Medical Association
Medicine
Entering the Era of Molecular-Targeted Precision Surgery in Recurrent Prostate Cancer
Journal of Nuclear Medicine
Medicine
Nuclear Medicine
Radiology
Imaging
Microsatellite Instability May Predict Response to Sipuleucel-T in Patients With Prostate Cancer
Clinical Genitourinary Cancer
Oncology
Urology
Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men With Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial
Clinical Cancer Research
Cancer Research
Oncology
Sipuleucel-T: Autologous Cellular Immunotherapy for Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
Journal of Cancer
Oncology
A New Era Has Begun Since the Approval of Thrombolytic Therapy for Acute Ischemic Stroke in Japan
Clinical Neurology
Neurology
